Drew Marquardt, PhD, CEO
Thad Harroun, PhD, CSO
EDI is a newly formed lipid technology platform company. In our research pipeline is LipiPET, a new cancer diagnosis tracer for Positron Emission Tomography. The lipid soluble molecule will speed the diagnosis of cancer by targeting difficult tumors, using less radioactivity while lowering scanning costs, improving patient throughput, and is inherently bio-safe.
Cancer is the third leading cause of death in Canada. Advances in cancer diagnosis and treatment are being led by improvements in molecular imaging; the ability to track the disease through pictures generated with injected radioactive biomarkers. There is a need for early diagnosis in all market segments amidst a growing healthcare awareness. There is especially increasing demand for targeted reagents in oncology amidst an aging population. LipiPET is the first radio-pharmaceutical designed for liposomal delivery for the target of difficult cancers such as brain and pancreatic cancers.
Milestones/Successes to date
EDI announced in November 2014 that its research partner Jeffrey Atkinson (Brock University), received a $30,000 grant from the Ontario Centres of Excellence (OCE) to help bring LipiPET to market. EDI provided matched funds to augment this OCE Voucher for Innovation and Productivity. This venture has resulted in a Brock chemistry PhD student receiving training from the Ontario's TalentEdge/Connect Canada Internship Program. The internship came to a conclusion December 2015. We are currently pursuing IP protection for this technology.
How has Innovate Niagara / BioLinc helped you achieve success so far?
EDI is pleased to partner with BioLinc and Innovate Niagara. Through them, we have gained access to knowledgeable R&D partners and important market research. We look forward to continuing our relationship and the ongoing development of key aspects of our business plan.
Being an entrepreneur means…
Taking action and responsibility for your own success.